Dyno Therapeutics and Roche have partnered to develop gene therapies for neurological diseases.
As part of the deal, Dyno will design adeno-associated virus (AAV) capsids with improved performance, while Roche will take charge of the later stages, including preclinical, clinical, and commercialization efforts. Dyno is set to receive $50 million upfront, with the potential to earn over $1 billion in milestone payments and royalties as the project progresses.
This partnership builds on their earlier 2020 agreement and focuses on using Dyno’s AI-driven platform to create next-generation AAV vectors that could transform gene delivery.
Using Dyno's AI-driven CapsidMap platform, the collaboration aimes to create more effective and manufacturable AAV capsids. Dyno focused on designing the capsids, while Roche and Spark handled clinical and commercial efforts, with the deal potentially worth over $1.8 billion in milestone payments.